ArticleEuropean journal of nuclear medicine and molecular imaging2026
Fully automated spleen segmentation predicts progression-free survival in HCC patients following transarterial radioembolization.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTransarterial radioembolization (TARE) is a well-established treatment for unresectable hepatocellular carcinoma (HCC), though its effects on non-tumorous tissue remain a concern. In particular, the prognostic relevance of splenic volume changes after TARE is not fully understood. This study aimed to assess imaging-derived markers-specifically splenic volume dynamics-as predictors of disease progression.
methodsWe retrospectively analyzed laboratory and imaging data from 73 patients with histologically or imaging-confirmed HCC who underwent TARE with Yttrium-90 (
resultsA relative increase in splenic volume at 3 months was the only independent predictor of progression-free survival (PFS), yielding a ROC-AUC of 0.86 (95%-CI: 0.76-0.95). An increase of 18% or more most accurately identified patients with early disease progression (< 12 months) with a sensitivity 0.74 and specificity 0.97, outperforming conventional clinical and laboratory parameters, including two-dimensional craniocaudal spleen measurements.
conclusionsAutomated splenic volumetry showed superior prognostic value over traditional markers in HCC patients treated with TARE. A post-treatment increase in spleen volume represents an additional, robust, and readily accessible imaging biomarker for early risk stratification and individualized treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.